STING1 and neoplasm: By converging on shared immunometabolic nodes, they offer modular approaches to complement existing ICIs—provided future studies resolve tumor-type-specific pathway dependencies (e.g., STING activation in rectal vs. lung cancer) and integrate metabolomic profiling into clinical trial stratification.